Cargando…

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab

OBJECTIVE: Here we report a case of a splenectomized white woman with natalizumab-associated progressive multifocal leukoencephalopathy (PML), occurring as early as after 11 infusions and provide blood fluorescence-activated cell sorting (FACS) analyses before and after natalizumab treatment. DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, De-Hyung, Waschbisch, Anne, Lämmer, Alexandra B, Doerfler, Arnd, Schwab, Stefan, Linker, Ralf A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854515/ https://www.ncbi.nlm.nih.gov/pubmed/24107235 http://dx.doi.org/10.1186/1742-2094-10-123

Ejemplares similares

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

Baseline Magnetic Resonance Imaging of the Optic Nerve Provides Limited Predictive Information on Short-Term Recovery after Acute Optic Neuritis
por: Berg, Sebastian, et al.
Publicado: (2015)

Visual Search as a Tool for a Quick and Reliable Assessment of Cognitive Functions in Patients with Multiple Sclerosis
por: Utz, Kathrin S., et al.
Publicado: (2013)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis
por: Waschbisch, Anne, et al.
Publicado: (2011)

Vascular pathology in multiple sclerosis: mind boosting or myth busting?
por: Waschbisch, Anne, et al.
Publicado: (2011)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Demyelinating disease and anti-N-methyl-D-aspartate receptor immunoglobulin G antibodies: a case report
por: Waschbisch, Anne, et al.
Publicado: (2014)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
por: Yao, Karen, et al.
Publicado: (2008)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2008)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
por: Antoniol, Caroline, et al.
Publicado: (2015)

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2020)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2010)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
por: Herold, Tina Rike, et al.
Publicado: (2012)

Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study
por: Bridel, Claire, et al.
Publicado: (2015)

Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates
por: Rekik, Arwa, et al.
Publicado: (2022)

Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

JC virus detection and JC virus-specific immunity in natalizumab-treated Multiple Sclerosis patients
por: Mancuso, Roberta, et al.
Publicado: (2012)

Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
por: Vivekanandan, Govinathan, et al.
Publicado: (2021)

T Lymphocyte Serotonin 5-HT(7) Receptor Is Dysregulated in Natalizumab-Treated Multiple Sclerosis Patients
por: Reverchon, Flora, et al.
Publicado: (2022)

Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients
por: Waschbisch, Anne, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mr8phlov4487n1kqraa8bi4etb